Navigation Links
Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
Date:9/11/2007

GAITHERSBURG, Md., Sept. 11 /PRNewswire/ -- As the Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) and Drug Safety and Risk Management Advisory Committee (DSRMAC) meet today to discuss questions related to erythropoiesis-stimulating agents (ESA's), Ortho Biotech reiterates its position on the following key issues that will be discussed:

* The studies being examined by the FDA Advisory Committees evaluated

hemoglobin targets above 13 grams per deciliter of blood (g/dL). In

March 2007, label guidance for all ESAs was revised to reflect a maximum

hemoglobin of 12 g/dL. When patients are treated according to the

label, PROCRIT(R) (Epoetin alfa) is a safe and effective therapeutic

option in the management of anemia in patients with chronic renal

failure (CRF).

* The weight of clinical evidence suggests that patients experience the

greatest benefit from a hemoglobin of between 10-12 g/dL, and that

patients who fall below a hemoglobin of 10 g/dL experience greater

morbidity and mortality, and are more likely to require a blood

transfusion.

* The company agrees that additional data are needed to determine how to

best identify and treat "ESA hyporesponders," or those patients who do

not respond adequately to ESA therapy.

PROCRIT represents a revolutionary treatment option in anemia management. ESAs, including PROCRIT, continue to be the only viable alternative to blood transfusions for the treatment of anemia in CRF patients. ESAs provide clear clinical benefit in CRF patients with regard to transfusion avoidance and improvements in physician-assessed and patient-reported outcomes. The benefits and risks of PROCRIT have been established in well-controlled clinical trials and observed in clinical experience over the past 18 years in four million patients worldwide across approved indications.

Ortho
'/>"/>

SOURCE Ortho Biotech Products, L.P.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
3. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
4. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
5. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
6. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
7. New Positive Pre-clinical Data for Active Biotechs RA Project I-3D
8. Prana Biotechnology Presents New Key Findings on PBT2
9. Oncolytics Biotech Inc. Announces Positive Clinical Data from U.S. Phase I REOLYSIN Trial
10. News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)... Facet Solutions, Inc. today announced that it has...trolled ACADIA(TM) IDE study for lumbar spinal ste...009," stated President and CEO, Geoff Pardo. "It i...omes that surgeons are seeing, and the ease with w...on people are diagnosed with lumbar spinal stenosi...
(Date:11/9/2009).... 9 Hill-Rom (NYSE: H...tion of a joint venture that will focus on the sal...face replacement systems that are intended to be s...for surfaces that are technologically obsolete or ...al leader in patient support systems and related t...
(Date:11/9/2009)...e/ -- Momentum is building for the early December...ond P-MEC India pharma ingredients, services and t...exhibitors from over 80 countries are expected...ts, being held on 1 - 3 December. ,, In additi...lude two new launches. BioPh India will focus on...
Breaking Medicine Technology:Facet Solutions Enrolls 100th Patient in US Pivotal IDE Study 2Hill-Rom and Encompass Group Form Joint Venture 2Hill-Rom and Encompass Group Form Joint Venture 3Hill-Rom and Encompass Group Form Joint Venture 4Hill-Rom and Encompass Group Form Joint Venture 5Forecast Looks Good for India Pharma Shows 2Forecast Looks Good for India Pharma Shows 3While you were sleeping 47771 1While you were sleeping 47771 2Natura Therapeutics and USF receive NIH grant to study green tea compound for Alzheimers 47769 1Natura Therapeutics and USF receive NIH grant to study green tea compound for Alzheimers 47769 2ESC Congress 2009 3A Worlds biggest cardiology meeting to be held in Barcelona 47767 1ESC Congress 2009 3A Worlds biggest cardiology meeting to be held in Barcelona 47767 2
...R-132 could provide a new therapeutic approach for...er, QUEBEC CITY, April 17, 2007 /PRNewswire-FirstC... biopharmaceutical company,focused on endocrine th...tlining in vivo data for its growth hormone-releas...ncer, at the American,Association for Cancer Resea...
...As previously announced, primary endpoint not met;...study treatment with ERBITUX,-, NEW YORK, April 16...ncorporated and Bristol-Myers Squibb Company today...a randomized,open-label, multi-center Phase III t...tecan to irinotecan alone in patients with,metasta...
Other Medicine Technology:AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 2AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 2Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 4Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 5Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 6Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 8Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 9
(Date:11/9/2009)...inds differences in mood despite similar weight lo...- Both a high-fat, low-carbohydrate diet such as t... diet appear to help people lose pounds over the c...ow-fat diets will result in long-term improvement ...of Archives of Internal Medicine . , People on...
(Date:11/9/2009)... Fast food chains are often blamed for the inc...by Fitness.com.au however finds that 80% of people...lity. , (PRWEB) November ...deo games were behind Australia’s obesity ep...st innocent bystanders. A recent survey commission...
(Date:11/9/2009)...mprehensive Cancer Network (NCCN) has posted a dra...raft paradigm for near-term comparative effectiven... The document introduces the NCCN Comparative Ther... that compares the risk-versus-benefit of differen...al Practice Guidelines in Oncology(TM). The paper ...
(Date:11/9/2009)... Highlighting a commitment to prov...ced entertainment and digital display technology o...ng-Term Care and Hospital Grade LCD HDTVs this wee... Aging 2009 annual meeting and exposition (booth #...e of "HealthView(TM)" Long-Term Care LCD HDTVs bri...
(Date:11/9/2009)...uestion of why this is so, however , ,...tomy, women with very dense breasts have a higher ...a new study shows. , Breast density has already...breast cancer, and experts have suspected that ver...reased risk of cancer recurrence at the site of th...
Breaking Medicine News(10 mins):Health News:To Feel Better, Low-Fat Diet May Be Best 2Health News:To Feel Better, Low-Fat Diet May Be Best 3Health News:Fitness.com.au Poll Finds 80% Blame Parents For Our Overweight Kids 2Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 2Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 3Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 4Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 2Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 3Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 4Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 5Health News:Dense Breasts Raise Risk of Cancer Recurrence 2Health News:Dense Breasts Raise Risk of Cancer Recurrence 3
..., Despite the commitments...lized training and practicing medicine in fields o... Honors College at Indiana University of Pennsylva...tients with different needs to Rebecca Pounds, who...
..., Chief Medical Officer, ... 2nd Annual Public Healthcare congress in Washingt...resentation, "Lessons Learned; Implementing a...ciency and security of patient information exchang...
..., Medical and nursing scr...ly redesigned site. With new products added and a ...ecoming the leading destination for hospital unifo...s new user friendly website. The new site has impl...
..., INDIANAPOLIS Public health professionals from...ianapolis for a national summit on ethical and pol...e medical community while preparing for a large-sc...Health, the Indiana University Center for Bioethic...
...Bipartisan Bill Improves Low-Income Help and Boost...Helps Ensure Access to Doctors, NEW YORK, July 15... and Senate voted overwhelmingly to override a,Whi...grams, boost health care quality with a system of ...
...OPTOMETRISTS LEAD WINNING PATIENT ACCESS COALITION...sociation (AOA) applauds Members of Congress from ...,s veto of legislation passed to stop massive,cuts... safeguard patient,access to eye and vision care t...
Other Medicine News:Health News:Robert E Cook Honors College Women In Medicine 2Health News:Robert E Cook Honors College Women In Medicine 3Health News:Robert E Cook Honors College Women In Medicine 4Health News:Robert E Cook Honors College Women In Medicine 5Health News:Robert E Cook Honors College Women In Medicine 6Health News:Orion Health's Dr. Chris Hobson Selected to Speak at World Congress Public Health Conference 2Health News:Orion Health's Dr. Chris Hobson Selected to Speak at World Congress Public Health Conference 3Health News:Medical And Nursing Scrubs Retailer Blue Sky Scrubs Unveils New Website 2Health News:Confronting Ethics of Pandemic Influenza Planning: 2008 Summit of the States 2Health News:AARP NY Thanks Congress for Keeping Medicare Fair, Overriding White House Veto 2Health News:AARP NY Thanks Congress for Keeping Medicare Fair, Overriding White House Veto 3Health News:American Optometric Association Applauds Override of Medicare Cuts 2Health News:American Optometric Association Applauds Override of Medicare Cuts 3
SYNCHRON LX®20 PRO
BN100
Bilitec 2000 Recorder
...y, pathology specimen imaging is now advancing tow...tion, analysis, interpretation and telepathology. ...gous to the change that occurred in radiology, and...departments and imaging clinics through the introd...
Medicine Products: